This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Sethi G , Pathak HB , Zhang H , Zhou Y , Einarson MB , Vathipadiekal V , Gunewardena S , Birrer MJ , Godwin AK
An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer
PLoS One. 2012 Oct;7(10) :e47086
PMID: 23056589 URL: http://www.ncbi.nlm.nih.gov/pubmed/23056589
AbstractTargeted therapies have been used to combat many tumor types; however, few have effectively improved the overall survival in women with epithelial ovarian cancer, begging for a better understanding of this deadly disease and identification of essential drivers of tumorigenesis that can be targeted effectively. Therefore, we used a loss-of-function screening approach to help identify molecular vulnerabilities that may represent key points of therapeutic intervention. We employed an unbiased high-throughput lethality screen using a 24,088 siRNA library targeting over 6,000 druggable genes and studied their effects on growth and/or survival of epithelial ovarian cancer (EOC) cell lines. The top 300 "hits" affecting the viability of A1847 cells were rescreened across additional EOC cell lines and non-tumorigenic, human immortalized ovarian epithelial cell lines. Fifty-three gene candidates were found to exhibit effects in all tumorigenic cell lines tested. Extensive validation of these hits refined the list to four high quality candidates (HSPA5, NDC80, NUF2, and PTN). Mechanistic studies show that silencing of three genes leads to increased apoptosis, while HSPA5 silencing appears to alter cell growth through G1 cell cycle arrest. Furthermore, two independent gene expression studies show that NDC80, NUF2 and PTN were significantly aberrantly overexpressed in serous adenocarcinomas. Overall, our functional genomics results integrated with the genomics data provide an important unbiased avenue towards the identification of prospective therapeutic targets for drug discovery, which is an urgent and unmet clinical need for ovarian cancer.
NotesSethi, Geetika Pathak, Harsh B Zhang, Hong Zhou, Yan Einarson, Margret B Vathipadiekal, Vinod Gunewardena, Sumedha Birrer, Michael J Godwin, Andrew K eng CA140323/CA/NCI NIH HHS/ K12 HD052027/HD/NICHD NIH HHS/ R01 CA140323/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2012/10/12 06:00 PLoS One. 2012;7(10):e47086. doi: 10.1371/journal.pone.0047086. Epub 2012 Oct 9.